Overview

A Phase 3 Study to Assess the Safety and Efficacy of 12 Months Treatment With Tigulixostat Compared to Allopurinol in Gout Patients With Hyperuricemia

Status:
Not yet recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.

Phase:

Phase 3

Details

Lead Sponsor:

LG Chem

Treatments:

Allopurinol